All NewsFDA BriefsOncology IconsSpecial ReportsVoices from the Field
Conference CoverageConference Listing
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPrecision Medicine
All PublicationsEvolving ParadigmsRoundtable Meetings SpotlightTargeted Therapies in Oncology
CME/CE
Case-Based Roundtable SeriesClinical TrialsPartnersPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
eNewsletterPrint Subscription
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
Multiple Myeloma
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2-Positive Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
Multiple Myeloma
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CME/CE
Advertisement

Addressing Skin-Related Toxicities Extends Positive Clinical Outcomes

Jun 19, 2020
Audrey Sternberg
Targeted Therapies in OncologyJune 1 2020
Volume 9
Issue 8

Management of treatment-associated dermatologic adverse events that commonly occur as a result of cytotoxic or targeted therapy is critical to prevent dose modifications or interruptions that could negatively affect clinical outcomes.

Management of treatment-associated dermatologic adverse events (AEs) that commonly occur as a result of cytotoxic or targeted therapy is critical to prevent dose modifications or interruptions that could negatively affect clinical outcomes. According to Mario E. Lacouture, MD, who presented data related to the incidence of dermatologic AEs as part of the virtually held 2020 Community Oncology Conference, assuring patients who develop these toxicities that their symptoms are manageable may motivate them to institute strategies that do not affect their treatment dose.1

“About 25% of all patients with cancer receiving systemic therapy will develop dermatologic toxicities at some point during their [course of treatment],” Lacouture said. “About a third of cancer survivors will report that the dermatologic toxicities they experienced during their treatment [had a negative] impact.”

Although the reasons why are still unclear, many of the dermatologic toxicities discussed in the presentation have also been correlated with improved survival in certain tumor types. Lacouture said informing patients of this relationship could be helpful in comforting those who develop difficult toxicities. “The same pathways and proteins that are critical for malignant behavior are also important and critical for the homeostasis and functioning of the skin, hair, and nails,” he said.

Lacouture, who is director of the Oncodermatology Program at Memorial Sloan Kettering Cancer Center in New York, New York, added that there seems to be a discordance between diagnoses and the need for dose modifications observed between oncologists and dermatologists when patients present with dermatologic AEs, for which he hopes increased clinician education would help reduce.

“Dermatologic adverse events are usually class based and mechanism based. It is easy to determine what therapy a patient is receiving just by looking at their skin, and in some cases, hair or nails,” Lacouture said.

Skin Rash

Agents blocking the epidermal growth factor receptor (EGFR) have been strongly associated with dermatologic AEs, with about two-thirds of patients developing an acneiform rash that Lacouture said could have “disfiguring” effects on the face, chest, scalp, and upper back.

This AE is one of the most common reasons for dose modifications or interruptions, calls to the office, and unplanned visits that are caused by EGFR inhibitors (FIGURE).1

For first- and second-generation tyrosine kinase inhibitors as well as monoclonal antibodies inhibiting EGFR, prophylactic therapy is key for managing this dermatologic AE.

HER2 agents can also cause acneiform rash at a lower severity, which means a more reactive management strategy can be employed.

In the ARCHER 1042 (NCT01465802) phase 2 trial of patients treated with the EGFR inhibitor dacomitinib (Vizimpro), the addition of prophylactic oral doxycycline reduced the incidence of grade 2 or greater skin toxicity by over half as compared with a reactive management strategy in patients with non–small cell lung cancer (23.2% vs 46.6%). Applying topical steroids plus an oral probiotic was also an effective strategy for reducing the incidence of dermatologic AEs compared with placebo, but the benefits were less significant.2

Nail Toxicities

Another AE commonly occurring in patients treated with targeted agents is paronychia, a painful inflammation and infection around the lateral sides of the fingernails and toenails, arising in about 25% of patients treated with EGFR inhibitors. This manifestation of paronychia can also be seen in patients receiving HER2 or mTOR inhibitors, but at lower rates.

Paronychia under the nail plate can occur in patients receiving taxane chemotherapy. One retrospective study demonstrated that more than 80% of patients treated with docetaxel (n = 55) experienced some changes to their nails over the course of treatment, with up to 43% of patients reporting difficulties doing daily activities.3

Lacouture recommended that clinicians obtain a bacterial culture every time patients present with a discharging lesion because the incidence of gram-negative secondary infections is high, with about 40% of patients with paronychia developing gram-negative organisms at the site of infection. He recommended that AEs of grade 1/2 in severity be treated with over-the-counter topical antiseptics that patients can soak their nails in. AEs of grade 3 or higher can be managed with oral antibiotics based on sensitivity, with some patients requiring partial or full nail avulsion performed by a podiatrist or dermatologist.

To prevent taxane-induced nail changes, Lacouture said patients can have their hands and feet cooled during therapy administration based on findings from a study showing that the use of a frozen glove was effective at reducing negative effects on the nail bed. Comparing 1 gloved hand with an ungloved hand in all treated patients, all-grade events were observed at a rate of 51% versus 11%.4

Added to this, Lacoutre emphasized that the use of a cooling glove has positive effects that extend beyond relieving discomfort on the surface of the skin. “You are also able to reduce neuropathy with the cooling of the hands and feet in patients receiving taxanes, and this has been a welcoming additional benefit in our patients.”

Hand-Foot Skin Reaction

Patients treated with VEGFR or PDGFR inhibitors are susceptible to developing a reaction in the palms and soles that is characterized by painful blisters and hyperkeratosis. Hand-foot syndrome usually happens within the first 6 weeks of treatment and can be so severe that the pain prevents patients from walking.

Once it has occurred, topical anesthetics and anti-inflammatory drugs are used to manage the sores. As prophylactic therapy, the only study with evidence of treatment benefit was a case of 871 patients with advanced hepatocellular cancer treated with sorafenib (Nexavar) who also received best supportive care with or without 10% urea-based cream 3 times daily. All-grade incidence of hand-foot syndrome was lower in the group that received the urea-based cream (56.0%) versus the group that received best supportive care alone (73.6%) at 12 weeks.5

“This is an inexpensive intervention,” Lacoutre said. “Patients would apply this on their palms and soles 3 times per day.”

References

  1. Lacouture ME. Clinical update: skin related toxicities in cancer care. Data made available as part of the virtual platform for the 2020 Community Oncology Alliance Annual Conference; April 23-24, 2020.
  2. Lacouture ME, Keefe DM, Sonis S, et al. A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. Ann Oncol. 2016;27(9):1712‐1718. doi:10.1093/annonc/ mdw227
  3. Winther D, Saunte DM, Knap M, Haahr V, Jensen AB. Nail changes due to docetaxel—a neglected side effect and nuisance for the patient. Support Care Cancer. 2007;15(10):1191‐1197. doi:10.1007/s00520-007-0232-0
  4. Scotté F, Tourani JM, Banu E, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol. 2005;23(19):4424‐4429. doi:10.1200/ JCO.2005.15.651
  5. Ren Z, Zhu K, Kang H, et al. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33(8):894‐900. doi:10.1200/JCO.2013.52.9651
Articles in this issue

Neoadjuvant Therapy Impresses in I-SPY 2 Trial for Breast Cancer
Neoadjuvant Therapy Impresses in I-SPY 2 Trial for Breast Cancer
Community Practice Mergers and Acquisitions Rise Steeply Over 2  Years, COA Report Reveals
Community Practice Mergers and Acquisitions Rise Steeply Over 2 Years, COA Report Reveals
HITTING THE TARGET: Multigene Tests Gain Foothold in More Clinical Settings
HITTING THE TARGET: Multigene Tests Gain Foothold in More Clinical Settings
Comorbid Toxicities Can Cloud Differential Diagnosis for Immune-Related AEs
Comorbid Toxicities Can Cloud Differential Diagnosis for Immune-Related AEs
Innovative Clinical Trial Design Can Unlock Best Outcomes in Ovarian Cancer
Innovative Clinical Trial Design Can Unlock Best Outcomes in Ovarian Cancer
Fecal Microbiota Transplant May Emerge as a Treatment Strategy in Melanoma Following Immunotherapy Failure
Fecal Microbiota Transplant May Emerge as a Treatment Strategy in Melanoma Following Immunotherapy Failure
New Intralesional Therapy Combinations Are Poised to Expand Beyond the Oncology Setting
New Intralesional Therapy Combinations Are Poised to Expand Beyond the Oncology Setting
Ease of Use  With Subcutaneous Daratumumab Supplants the Intravenous Formulation as Standard of Care  Across Settings in Myeloma
Ease of Use With Subcutaneous Daratumumab Supplants the Intravenous Formulation as Standard of Care Across Settings in Myeloma
Investigators Employ a Range of Novel and Established Systemic Therapies for Advanced Glioblastoma
Investigators Employ a Range of Novel and Established Systemic Therapies for Advanced Glioblastoma
As Cancer Care Delivery Models Shift, Practices Must Decide Whether to Take on Extra Risk
As Cancer Care Delivery Models Shift, Practices Must Decide Whether to Take on Extra Risk
Diverse Populations  Necessitate Innovative Combinations in Ovarian Cancer
Diverse Populations Necessitate Innovative Combinations in Ovarian Cancer
Global Pandemic Paves Way to Modernize Clinical Trials
Global Pandemic Paves Way to Modernize Clinical Trials
Addressing Skin-Related Toxicities Extends Positive Clinical Outcomes
Addressing Skin-Related Toxicities Extends Positive Clinical Outcomes
Anti–PD-1/PD-L1 Immunotherapies Continue to Impress in Unique Combinations
Anti–PD-1/PD-L1 Immunotherapies Continue to Impress in Unique Combinations
Related Videos
Related Content

Antitumor Activity Is Reported for Lurbinectedin in 4 Molecular Subtypes of SCLC

June 2nd 2023

Liquid Biopsy Holds Promise in Prostate Cancer Diagnosis

June 1st 2023

Breast Cancer Conference Addresses HER2-Low Therapeutic Subset

May 31st 2023

Long-term Benefit of Amivantamab Continues in Postplatinum NSCLC

May 30th 2023

Neoadjuvant Immunotherapy Expands Its Reach in Metastatic Melanoma

May 29th 2023

Driving Precision Oncology With Biomarker Data

May 28th 2023

Antitumor Activity Is Reported for Lurbinectedin in 4 Molecular Subtypes of SCLC

June 2nd 2023

Liquid Biopsy Holds Promise in Prostate Cancer Diagnosis

June 1st 2023

Breast Cancer Conference Addresses HER2-Low Therapeutic Subset

May 31st 2023

Long-term Benefit of Amivantamab Continues in Postplatinum NSCLC

May 30th 2023

Neoadjuvant Immunotherapy Expands Its Reach in Metastatic Melanoma

May 29th 2023

Driving Precision Oncology With Biomarker Data

May 28th 2023

Antitumor Activity Is Reported for Lurbinectedin in 4 Molecular Subtypes of SCLC

June 2nd 2023

Liquid Biopsy Holds Promise in Prostate Cancer Diagnosis

June 1st 2023

Breast Cancer Conference Addresses HER2-Low Therapeutic Subset

May 31st 2023

Long-term Benefit of Amivantamab Continues in Postplatinum NSCLC

May 30th 2023

Neoadjuvant Immunotherapy Expands Its Reach in Metastatic Melanoma

May 29th 2023

Driving Precision Oncology With Biomarker Data

May 28th 2023
Related Content

Antitumor Activity Is Reported for Lurbinectedin in 4 Molecular Subtypes of SCLC

Antitumor Activity Is Reported for Lurbinectedin in 4 Molecular Subtypes of SCLC

June 2nd 2023
Article

Lurbinectedin yielded a value of 6.52 nM on the key pharmacological efficacy variable IC50, according to a poster presented at the 2023 Annual Meeting of the American Association for Cancer Research

Read More


Liquid Biopsy Holds Promise in Prostate Cancer Diagnosis

Liquid Biopsy Holds Promise in Prostate Cancer Diagnosis

June 1st 2023
Article

According to Joshua M. Lang, MD, MS, the importance of molecular understanding, especially in initially focusing on the genetics of PCa and how that can inform new therapies, has been one of the revolutions in PCa.

Read More


Breast Cancer Conference Addresses HER2-Low Therapeutic Subset

Breast Cancer Conference Addresses HER2-Low Therapeutic Subset

May 31st 2023
Article

Joyce O’Shaughnessy, MD, highlights advances in breast cancer management which will be presented at an upcoming medical meeting.

Read More


Long-term Benefit of Amivantamab Continues in Postplatinum NSCLC

Long-term Benefit of Amivantamab Continues in Postplatinum NSCLC

May 30th 2023
Article

Amivantamab elicited an objective response rate of 37% per investigator assessment, with a median duration of response of 12.5 months, according to long-term data from the CHRYSALIS trial.

Read More


Neoadjuvant Immunotherapy Expands Its Reach in Metastatic Melanoma

Neoadjuvant Immunotherapy Expands Its Reach in Metastatic Melanoma

May 29th 2023
Article

A number of novel immunotherapies, such as PD-1 inhibitors and targeted drug therapies with BRAF and MEK inhibitors, have become available for managing advanced melanoma.

Read More


Driving Precision Oncology With Biomarker Data

Driving Precision Oncology With Biomarker Data

May 28th 2023
Article

Today, we are in the heyday of biomarker discovery, utilization, and translation to clinical practice.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.